Beatriz Lara
YOU?
Author Swipe
View article: La transformación digital y su aporte en los procesos de gestión empresarial
La transformación digital y su aporte en los procesos de gestión empresarial Open
We have heard nowadays a lot about the concept of digital transformation; however, not everyone is clear about its meaning and applicability. This paper seeks to expand the concepts of digital transformation and how they currently contribu…
View article: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effectiveness and Safety of IMU-838, in Combination with oseltamivir, in Adults with Coronavirus-19- a feasibility trial
Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effectiveness and Safety of IMU-838, in Combination with oseltamivir, in Adults with Coronavirus-19- a feasibility trial Open
Background The global urgency for effective treatments against SARS-CoV-2 infections, causing COVID-19, remains paramount. One promising avenue is repurposing existing medications. IMU-838, a dihydroorotate dehydrogenase (DHODH) inhibitor,…
View article: Safety of immunotherapy with Alternaria alternata glutaraldehyde–polymerized allergen extract in adults and children
Safety of immunotherapy with Alternaria alternata glutaraldehyde–polymerized allergen extract in adults and children Open
Background: Allergies to fungi, such as Alternaria alternata, are significant contributors to respiratory conditions like asthma and rhinitis. Immunotherapy with native A. alternata extracts often results in high rates of adverse reactions…
View article: Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial
Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial Open
Objective To evaluate whether a structured online supervised group physical and mental health rehabilitation programme can improve health related quality of life compared with usual care in adults with post-covid-19 condition (long covid).…
View article: A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 Open
Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in i…
View article: Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry
Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry Open
Alpha-1 antitrypsin deficiency (AATD) is characterised by low serum levels of alpha-1 antitrypsin (AAT) and predisposes to the development of pulmonary emphysema and liver disease [1]. This deficiency is considered a rare condition and its…
View article: Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the <b>IONIC</b> trial protocol
Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the <b>IONIC</b> trial protocol Open
Background Globally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existing medications may offer the best hope for treating patients with COVID-19 to curb the pandemic. IMU-838 is a …
View article: Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey
Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey Open
Background There is an emerging understanding that coronavirus disease 2019 (COVID-19) is associated with increased incidence of pneumomediastinum (PTM). We aimed to determine its incidence among patients hospitalised with COVID-19 in the …
View article: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus-19 – The IONIC Trial Protocol
Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus-19 – The IONIC Trial Protocol Open
Background Globally there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID 19). Repurposing existing medications may offer the best hope for treating COVID 19 patients to curb the pandemic. IMU-838 is a dihydr…
View article: Long-term effect of α<sub>1</sub>-antitrypsin augmentation therapy on the decline of FEV<sub>1</sub>in deficient patients: an analysis of the AIR database
Long-term effect of α<sub>1</sub>-antitrypsin augmentation therapy on the decline of FEV<sub>1</sub>in deficient patients: an analysis of the AIR database Open
Background Patients with ZZ (Glu342Lys) α-1-antitrypsin deficiency (ZZ-AATD) who received augmentation therapy with α-1-antitrypsin (AAT) in randomised controlled trials over 2–3 years failed to show a significant reduction of the annual d…
View article: Correction to: Rehabilitation Exercise and psycholoGical support After covid-19 InfectioN’ (REGAIN): a structured summary of a study protocol for a randomised controlled trial
Correction to: Rehabilitation Exercise and psycholoGical support After covid-19 InfectioN’ (REGAIN): a structured summary of a study protocol for a randomised controlled trial Open
An amendment to this paper has been published and can be accessed via the original article.
View article: Research priorities in α<sub>1</sub>-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
Research priorities in α<sub>1</sub>-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration Open
α 1 -antitrypsin deficiency (AATD) is a rare and under-recognised genetic condition. Owing to its low prevalence, international initiatives are key for conducting high-quality research in the field. From July 2018 to December 2019, the Eur…
View article: Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown
Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown Open
Background and purpose The COVID‐19 epidemic is affecting almost all individuals worldwide, and patients with Alzheimer’s disease (AD) and amnesic mild cognitive impairment (MCI) are particularly at risk due to their characteristics and ag…
View article: Protocol for the EARCO Registry: a pan-European observational study in patients with α<sub>1</sub>-antitrypsin deficiency
Protocol for the EARCO Registry: a pan-European observational study in patients with α<sub>1</sub>-antitrypsin deficiency Open
Rationale and objectives Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural…
View article: Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)
Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT) Open
In this large cohort with a long follow-up, we observed a very variable decline of FEV1. However, the mean FEV1 decline was similar to that observed in large cohorts of smoking-related COPD. Tobacco consumption, previous pneumonia and bett…
View article: Characterization of Novel Missense Variants of <i>SERPINA1</i> Gene Causing Alpha-1 Antitrypsin Deficiency
Characterization of Novel Missense Variants of <i>SERPINA1</i> Gene Causing Alpha-1 Antitrypsin Deficiency Open
The SERPINA1 gene is highly polymorphic, with more than 100 variants described in databases. SERPINA1 encodes the alpha-1 antitrypsin (AAT) protein, and severe deficiency of AAT is a major contributor to pulmonary emphysema and liver disea…
View article: Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature
Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature Open
Alpha-1 antitrypsin (AAT) functions primarily to inhibit neutrophil elastase, and its deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD). The putative protective serum concentration is gen…
View article: Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide
Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide Open
The alpha-1 antitrypsin (AAT) haplotype Pi*S, when inherited along with the Pi*Z haplotype to form a Pi*SZ genotype, can be associated with pulmonary emphysema in regular smokers, and less frequently with liver disease, panniculitis, and s…
View article: Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene
Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene Open
Human SERPINA1 gene is located on chromosome 14q31-32.3 and is organized into three (IA, IB, and IC) non-coding and four (II, III, IV, V) coding exons. This gene produces α1-antitrypsin (A1AT), a prototypical member of the serpin superfami…
View article: Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults
Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults Open
Specific immunotherapy using natural modified allergen vaccines is safe to treat allergic patients, even at higher doses and in mixtures of unrelated allergen extracts. The percentage of adverse reactions detected is lower than those repor…